SEQUOIA-HCM
2024
Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM
In 282 patients with symptomatic obstructive HCM, aficamten improved peak oxygen uptake on exercise testing compared with placebo.
Result
Primary endpoint: Change in peak oxygen uptake (pVO2) at 24 weeks
Aficamten increased pVO2 by a least-squares mean difference of 1.74 mL/kg/min (95% CI 1.04-2.44; P<0.001) vs placebo, with improvements in all 10 secondary endpoints.
- Subtopic
- myosin inhibitor
- Design
- Double-blind placebo-controlled RCT, phase 3
- Relevance
- Supporting: context rather than must-know.
- Source
- Maron MS, et al. N Engl J Med. 2024;390(20):1849-1861.doi 10.1056/NEJMoa2401424
Discussion & critique
Functional surrogate endpoint over 24 weeks rather than hard outcomes. Positioned aficamten as a next-generation cardiac myosin inhibitor with a potentially simpler titration/monitoring profile than mavacamten.